不是神药，文献说化疗时结合用胸腺肽，可增加化疗效果，减少毒性。

来源: 于 2022-01-19 06:37:36 [博客] [旧帖] [给我悄悄话] 本文已被阅读：次

机器翻译：

《胸腺素α1治疗癌症：从基础研究到临床应用》https://www.sciencedirect.com/science/article/abs/pii/S0192056100000758?via%3Dihub 
摘要
许多研究探索了免疫疗法单独或与常规疗法联合对实验性癌症和人类癌症的影响。有证据表明，胸腺素 α1 (Tα1) 和低剂量干扰素 (IFN) 或白细胞介素 (IL)-2 的联合治疗在恢复因肿瘤生长和/或细胞抑制药物抑制的几种免疫反应方面非常有效。此外，与特异性化疗相结合时，它们能够增加化疗的抗肿瘤作用，同时显着降低治疗的一般毒性。本期综述了在实验性癌症和人类癌症中使用这种联合化学免疫治疗方法的优势。


Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application，https://www.sciencedirect.com/science/article/abs/pii/S0192056100000758?via%3Dihub 
Abstract
Many studies have explored the effects of immunotherapy, alone or in combination with conventional therapies, on both experimental and human cancers. Evidence has been provided that combined treatments with thymosin alpha 1 (T α 1) and low doses of interferon (IFN) or interleukin (IL)-2 are highly effective in restoring several immune responses depressed by tumor growth and/or cytostatic drugs. In addition, when combined with specific chemotherapy, they are able to increase the anti-tumor effect of chemotherapy while markedly reducing the general toxicity of the treatment. The advantages of using this combined chemo-immunotherapeutic approach in experimental and human cancers are reviewed in this issue.

 

 

Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application
Abstract
Many studies have explored the effects of immunotherapy, alone or in combination with conventional therapies, on both experimental and human cancers. Evidence has been provided that combined treatments with thymosin alpha 1 (T α 1) and low doses of interferon (IFN) or interleukin (IL)-2 are highly effective in restoring several immune responses depressed by tumor growth and/or cytostatic drugs. In addition, when combined with specific chemotherapy, they are able to increase the anti-tumor effect of chemotherapy while markedly reducing the general toxicity of the treatment. The advantages of using this combined chemo-immunotherapeutic approach in experimental and human cancers are reviewed in this issue.